Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$14.74

0.13 (0.89%)

, SNY

Sanofi

$48.58

-0.25 (-0.51%)

12:00
09/13/17
09/13
12:00
09/13/17
12:00

Lexicon slides after NEJM publishes diabetes study results

Lexicon Pharmaceuticals after lower after the company announced earlier that the New England Journal of Medicine, or NEJM, published the results of the Phase 3 inTandem3 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of patients with type 1 diabetes on any background insulin therapy. The data were published online today in conjunction with presentation of these data at the European Association for the Study of Diabetes, or EASD, annual meeting. The study met its primary endpoint with statistical significance, demonstrating the superiority of sotagliflozin 400 mg compared to placebo in the proportion of patients with A1C less than7.0% at Week 24 and no episode of severe hypoglycemia and no episode of DKA after randomization. The responder rate for patients on sotagliflozin was approximately twice the rate as compared to placebo. The difference compared to placebo for patients treated with sotagliflozin was 13.4%, the company reported. The outcome on every secondary endpoint achieved statistical significance favoring sotagliflozin over placebo, including change from baseline in A1C, body weight, systolic blood pressure in patients with baseline SBP greater than or equal to130 mm Hg and bolus insulin. "Sotagliflozin demonstrated a generally well tolerated safety profile during a 24-week treatment period, with rates of treatment-emergent adverse events, serious adverse events, and discontinuations due to adverse events that were consistent with rates seen in two prior pivotal Phase 3 studies," Lexicon said. Lonnel Coats, Lexicon's president and CEO, added, "As we remain committed to advancing the science in diabetes and bringing innovative therapies to patients to help improve outcomes and ease the burden of managing their diabetes, we look forward to Sanofi's filing for global regulatory approval for type 1 diabetes in the first half of 2018." In midday trading, Lexicon shares have slid $1.39, or 9.46%, to $13.35.

LXRX

Lexicon

$14.74

0.13 (0.89%)

SNY

Sanofi

$48.58

-0.25 (-0.51%)

  • 13

    Sep

  • 13

    Sep

  • 13

    Sep

  • 25

    Sep

LXRX Lexicon
$14.74

0.13 (0.89%)

03/07/17
SBSH
03/07/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon price target raised to $28 from $24 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $28 saying the company's potential in diabetes remains underappreciated. Management's commentary on sotagliflozin should re-assure investors who remain unconvinced about the T1D thesis, Nochomovitz tells investors in a post-earnings research note. He keeps a Buy rating on Lexicon.
03/01/17
WEDB
03/01/17
NO CHANGE
WEDB
Lexicon price target raised to $38 from $33 at Wedbush
Wedbush analyst Liana Moussatos increased her price target on Lexicon after the FDA approved Lexicon's lead drug, Zermelo, for carcinoid syndrome. The analyst thinks that the company has several additional upcoming positive potential catalysts. She keeps an Outperform rating on the stock.
12/22/16
SBSH
12/22/16
NO CHANGE
Target $24
SBSH
Buy
Citi disagrees with market view on Lexicon Pharmaceuticals
After shares of Lexicon Pharmaceuticals fell 7% yesterday following data from the second Phase 3 testing sotagliflozin in Type 1 diabetes, Citi analyst Yigal Nochomovitz says he disagrees with the market view. Investors are "getting too bogged" down on the safety question, the analyst tells investors in a research note. The data "unambiguously solve a major clinical challenge" in Type 1, which is getting A1c lower without the expense of glycemic excursions and thus more hypos, Nochomovitz writes. He keeps a Buy rating on Lexicon with a $24 price target.
12/21/16
12/21/16
NO CHANGE

Lexicon's sotagliflozin meets primary endpoint in Phase 3 trial for diabetes
Lexicon Pharmaceuticals' pivotal inTandem2 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on optimized insulin therapy. Top-line results from the Phase 3 study showed that patients treated with sotagliflozin had mean A1C reductions from baseline of 0.39% on 200mg once daily sotagliflozin dose and 0.37% on 400mg once daily sotagliflozin dose as compared to a reduction of 0.03% on placebo after 24 weeks of treatment, meeting the study's primary endpoint. This statistically significant and clinically meaningful improvement in A1C for both doses of sotagliflozin was achieved with a favorable overall safety profile in the study, including rates of severe hypoglycemia similar to placebo and low overall rates of diabetic ketoacidosis.
SNY Sanofi
$48.58

-0.25 (-0.51%)

09/11/17
FBCO
09/11/17
NO CHANGE
Target $485
FBCO
Outperform
Regeneron, Sanofi asthma trial 'statistically significant,' says Credit Suisse
Credit Suisse analyst Alethia Young notes that Regeneron (REGN)/Sanofi (SNY) released top-line asthma results, and the overall trial was "statistically significant." Specifically, the trial hit in the overall population, but it is unclear if the trial was statistically significant in the low eosinophil level patients alone, she notes. The analyst reiterates an Outperform rating and $485 price target on Regeneron's shares.
08/30/17
08/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Sanofi (SNY) upgraded to Hold from Reduce at HSBC, with analyst Steve McGarry citing valuation. 2. M.D.C. Holdings (MDC) upgraded to Market Perform from Underperform at Wells Fargo with analyst Stephen East saying he sees "little reason the equity would move meaningfully lower" from current levels. 3. Ciena (CIEN) upgraded to Buy from Neutral at Citi with analyst Stanley Kovler saying the risk/reward is positive into third quarter results. 4. Six Flags (SIX) upgraded to Buy from Neutral at Hilliard Lyons with analyst Jeff Thomison citing improved valuation based on its 13% year-to-date pullback. 5. Prospect Capital (PSEC) upgraded to Market Perform from Underperform at Raymond James with analyst Robert Dodd saying he expects near-term earnings will cover the lower dividend run-rate but notes downside risk remains. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/30/17
HSBC
08/30/17
UPGRADE
Target $81
HSBC
Hold
Sanofi upgraded to Hold from Reduce at HSBC
HSBC analyst Steve McGarry upgraded Sanofi to Hold and increased its price target to $81 from $79 citing valuation and said he sees few catalysts to own the shares either.
07/31/17
ADAM
07/31/17
NO CHANGE
Target $522
ADAM
Buy
Dupixent authorization approval rate outweighs Q2 miss, says Canaccord
Regeneron (REGN) partner Sanofi (SNY) reported a "very high" 73%-83% prior authorization approval rate for Dupixent in Q2, which Canaccord analyst John Newman said outweighs the fact that sales for the drug at $30.6M were slightly below the $33M consensus forecast. The analyst, who sees rapid payor acceptance of Dupixent as "much more crucial" than the initial quarterly revenue, keeps a Buy rating and $522 price target on Regeneron shares.

TODAY'S FREE FLY STORIES

SYBX

Synlogic

$18.73

-0.52 (-2.70%)

09:40
09/19/17
09/19
09:40
09/19/17
09:40
Initiation
Synlogic initiated  »

Synlogic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

, KORS

Michael Kors

09:40
09/19/17
09/19
09:40
09/19/17
09:40
Options
Unusually active option classes on open September 19th »

Unusual total active…

KSU

Kansas City Southern

KORS

Michael Kors

AAOI

Applied Optoelectronics

$66.29

7.99 (13.71%)

RAD

Rite Aid

NKE

Nike

M

Macy's

EFX

Equifax

INTC

Intel

VIX

Volatility Index S&P 500 Options

AMD

AMD

$13.08

0.56 (4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 23

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 28

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 16

    Nov

NKE

Nike

09:37
09/19/17
09/19
09:37
09/19/17
09:37
Recommendations
Nike analyst commentary  »

Nike risk/reward remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

SMBK

SmartFinancial

$23.88

0.38 (1.62%)

09:36
09/19/17
09/19
09:36
09/19/17
09:36
Hot Stocks
SmartFinancial, Capstone Bancshares holders approve merger-related proposals »

SmartFinancial and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:35
09/19/17
09/19
09:35
09/19/17
09:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD edged…

PG

Procter & Gamble

09:34
09/19/17
09/19
09:34
09/19/17
09:34
Hot Stocks
Peltz says Procter & Gamble should have bought Method Soap »

Nelson Peltz of Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORI

Corium

$10.16

0.25 (2.52%)

, NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

09:33
09/19/17
09/19
09:33
09/19/17
09:33
Conference/Events
Mizuho to hold a conference »

Biotechnology CNS Deep…

CORI

Corium

$10.16

0.25 (2.52%)

NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

VYGR

Voyager Therapeutics

$17.36

1.01 (6.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

NVAX

Novavax

$1.12

-0.02 (-1.75%)

09:32
09/19/17
09/19
09:32
09/19/17
09:32
Hot Stocks
Novavax initiates Phase 1/2 trial of NanoFlu vaccine in older adults »

Novavax announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BSMX

Santander Mexico

09:32
09/19/17
09/19
09:32
09/19/17
09:32
Downgrade
Santander Mexico rating change  »

Santander Mexico…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPLR

Xplore Technologies

$3.50

-0.2 (-5.41%)

09:31
09/19/17
09/19
09:31
09/19/17
09:31
Hot Stocks
Xplore Technologies secures Android rugged tablet order »

Xplore Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 30

    Nov

SNE

Sony

09:31
09/19/17
09/19
09:31
09/19/17
09:31
Downgrade
Sony rating change  »

Sony downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
09/19/17
09/19
09:30
09/19/17
09:30
General news
The U.S. August housing starts report »

The U.S. August housing…

BSX

Boston Scientific

09:29
09/19/17
09/19
09:29
09/19/17
09:29
Hot Stocks
Boston Scientific's HeartLogic Diagnostic shows positive risk detection ability »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:28
09/19/17
09/19
09:28
09/19/17
09:28
Hot Stocks
Ubiquiti CEO to host Investor Update on September 26 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HQY

HealthEquity

$45.77

0.65 (1.44%)

09:26
09/19/17
09/19
09:26
09/19/17
09:26
Conference/Events
HealthEquity participates in a conference call with Chardan »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:26
09/19/17
09/19
09:26
09/19/17
09:26
Hot Stocks
Ubiquiti Board approves additional $100M stock repurchase program »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:23
09/19/17
09/19
09:23
09/19/17
09:23
Earnings
Ubiquiti narrows Q1 revenue view to $240M-$250M, consensus $234.5M »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LNDC

Landec

$12.80

-0.2 (-1.54%)

09:22
09/19/17
09/19
09:22
09/19/17
09:22
Hot Stocks
Landec provides update on impact from extreme weather events »

Landec provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BOBE

Bob Evans

$72.93

1.02 (1.42%)

, POST

Post Holdings

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Bob Evans (BOBE),…

BOBE

Bob Evans

$72.93

1.02 (1.42%)

POST

Post Holdings

AZO

AutoZone

TLGT

Teligent

$6.90

-0.29 (-4.03%)

WBA

Walgreens Boots Alliance

$82.60

0.1 (0.12%)

RAD

Rite Aid

APOG

Apogee Enterprises

$44.98

0.18 (0.40%)

EFX

Equifax

ALDX

Aldeyra

$9.10

0.2 (2.25%)

SNCR

Synchronoss

$16.75

0.64 (3.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 30

    Oct

  • 19

    Sep

PG

Procter & Gamble

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
Peltz says not asking for P&G CEO David Taylor to step down »

Nelson Peltz of Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOX

Amdocs

$64.13

1.64 (2.62%)

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Conference/Events
Amdocs participates in a conference call with Oppenheimer »

Conference call for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Hot Stocks
Tyler Technologies selected by Odessa, Texas for ERP solution »

Tyler Technologies signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Options
Overnight activity included 97 trades in SPX and 67 trades in VIX »

97 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

09:16
09/19/17
09/19
09:16
09/19/17
09:16
Hot Stocks
Air Products awarded oxygen supply contract by South Korean chemical company »

Air Products has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

, XYL

Xylem

09:15
09/19/17
09/19
09:15
09/19/17
09:15
Conference/Events
Cowen to hold a summit »

Industrial Innovation…

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

XYL

Xylem

WLDN

Willdan Group

$29.79

0.71 (2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 28

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.